Definitive radiotherapy for early stage hypopharyngeal cancer (T1-2N0M0): a retrospective study of clinical outcomes and prognostic factors.

Authors

Tsuyoshi Fukuzawa, Toshihisa Kuroki, Shigeto Kabuki, Yoshitsugu Matsumoto, Kenji Okami, Akitomo Sugawara

Published in

Journal of radiation research. Sep 30, 2026. Epub Sep 30, 2026.

Abstract

Hypopharyngeal carcinoma (HPC) is an aggressive malignancy that is often diagnosed at an advanced stage. Advances in narrowband imaging have increased the early detection rate of HPC. Definitive radiotherapy (RT) is a noninvasive, organ-preserving option recommended for early stage (T1-2N0M0) disease; however, its clinical outcomes remain limited. This study retrospectively evaluated the clinical outcomes of definitive RT for early stage HPC. We retrospectively analyzed 55 patients with early stage HPC who were treated with RT between 2013 and 2023. Treatments included volumetric-modulated arc therapy or three-dimensional conformal radiotherapy with elective nodal irradiation. Chemoradiotherapy was administered to selected patients with stage T2 disease. Survival outcomes were assessed using Kaplan-Meier and Cox models. Median follow-up was 43 months. The 5-year overall survival (OS), progression-free survival, and cancer-specific survival rates were 65%, 57%, and 82%, respectively. Local control, locoregional control and laryngeal preservation rate at 5 years were 79%, 74%, and 91%, respectively. Initial recurrences were locoregional, with local recurrence in 10 of 55 patients (18%) and regional lymph node recurrence in three of 55 patients (5.4%). In univariate analysis, older age (≧71 years) and a history of esophageal cancer were associated with significantly worse OS. The multivariate analysis confirmed that older age and a history of esophageal cancer were independent predictors of OS. RT for early stage HPC provides favorable oncological outcomes and high rates of laryngeal preservation. However, OS was strongly influenced by age and a history of esophageal cancer, highlighting the need for treatment selection and follow-up, including surveillance for second primary esophageal cancer.

PMID:
42814863
Bibliographic data and abstract were imported from PubMed on 01 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.